Sulphamethoxazole/trimethoprim: Pharmacokinetic studies in patients with chronic renal failure

Baethke, R; Golde, G.; Gahl, Gerhard M.

doi:10.1007/bf00635802

Cited by 32 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to findings in non-dialysis dependent renally impaired patients, unchanged SMX concentrations do not increase in patients with renal impairment sufficient to necessitate dialysis [8]. However, the concentrations of TMP and of SMX metabolites increased in dialysis-dependent patients compared to patients with severe non-dialysis dependent renal impairment [8].…”

Section: Reviewmentioning

confidence: 55%

“…However, the concentrations of TMP and of SMX metabolites increased in dialysis-dependent patients compared to patients with severe non-dialysis dependent renal impairment [8]. Surprisingly, given the drug’s prolonged use, only limited description of the effect of dialysis on removal of each drug during a dialysis session is available; none for critically ill patients.…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Cotrimoxazole - optimal dosing in the critically ill

Brown

2014

Ann Intensive Care

View full text Add to dashboard Cite

The optimum dosage regimen for cotrimoxazole in the treatment of life threatening infections due to susceptible organisms encountered in critically ill patients is unclear despite decades of the drug’s use. Therapeutic drug monitoring to determine the appropriate dosing for successful infection eradication is not widely available. The clinician must utilize published pharmacokinetic, pharmacodynamic, and effective inhibitory concentration information to determine potential dosing regimens for individual patients when treating specific pathogens. Using minimum inhibitory concentrations known to successfully block growth for target pathogens, the pharmacokinetics of both trimethoprim and sulfamethoxazole can be utilized to establish empiric dosing regimens for critically ill patients while considering organ of clearance impairment. The author’s recommendations for appropriate dosing regimens are forwarded based on these parameters.

show abstract

Section: Reviewmentioning

confidence: 55%

Section: Reviewmentioning

confidence: 99%

Cotrimoxazole - optimal dosing in the critically ill

Brown

2014

Ann Intensive Care

View full text Add to dashboard Cite

show abstract

“…The apparent volume of distribution for TMP is around 100:1 (69-138 I) but only around 13 1 (l 0-16 I) in the case of SMX, which indicates a far greater tissue (cell) penetration for TMP than for SMX (BERGAN and BRODWALL 1972a;BUNGER et al 1961;BUTTNER 1973, 1974;. In reduced renal function, the volume of distribution is increased, especially in the case of SMXa, presumably as a secondary feature to reduced protein binding (BAETHKE et al 1972;BUTTNER et al 1964;RIEDER et al 1974c;WELLING et al 1973) and to qualitative and quantitative changes in the body fluids (RIEDER et al 1974c). In reduced renal function, the volume of distribution is increased, especially in the case of SMXa, presumably as a secondary feature to reduced protein binding (BAETHKE et al 1972;BUTTNER et al 1964;RIEDER et al 1974c;WELLING et al 1973) and to qualitative and quantitative changes in the body fluids (RIEDER et al 1974c).…”

Section: Plasmamentioning

confidence: 99%

Inhibition of Folate Metabolism in Chemotherapy

Hitchings¹

1983

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

“…A routine adminis tration of the SM/TM combination has been warned against, if the serum creatinine is over 2 mg% [1].…”

Section: Discussionmentioning

confidence: 99%

Sulfadiazine-Trimethoprim Combination in the Treatment of Urinary Tract Infections

1977

View full text Add to dashboard Cite

In a clinical double-blind study on 198 patients with a urinary tract infection, no differences were found between comparable groups treated with either sulfadiazine (SD) 1,000 mg/trimethoprim (TM) 320 mg or sulfamethoxazole (SM) 1,600 mg/trimethoprim 320 g daily for 2 weeks. The favorable results were obtained according to the bacteriological control in 85 and 79%, respectively. Also the incidence of side effects was the same (22 and 24%, resp.). The number of cases within which the treatment had to be discontinued did not differ percentually, either (6.6 and 8.4%, resp.). Based on the bacteriological sensitivity tests and the clinical trial, the authors conclude that TM can be combined with SD as well as with SM. Pharmacokinetic advantages, like a lower protein-binding and a lesser metabolism, may even make SD more preferable.

show abstract

Sulphamethoxazole/trimethoprim: Pharmacokinetic studies in patients with chronic renal failure

Cited by 32 publications

References 15 publications

Cotrimoxazole - optimal dosing in the critically ill

Cotrimoxazole - optimal dosing in the critically ill

Inhibition of Folate Metabolism in Chemotherapy

Sulfadiazine-Trimethoprim Combination in the Treatment of Urinary Tract Infections

Contact Info

Product

Resources

About